Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protagonist Therapeutics, Inc. - Common Stock (NQ: PTGX ) 38.89 -0.62 (-1.57%) Streaming Delayed Price Updated: 2:15 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 193,963 Open 39.20 Bid (Size) 38.87 (2) Ask (Size) 38.94 (6) Prev. Close 39.51 Today's Range 38.50 - 39.68 52wk Range 21.43 - 48.89 Shares Outstanding 59,598,018 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 December 19, 2024 Via ACCESSWIRE Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting December 09, 2024 Via ACCESSWIRE Performance YTD +66.05% +66.05% 1 Month -13.25% -13.25% 3 Month -13.44% -13.44% 6 Month +21.99% +21.99% 1 Year +65.91% +65.91% More News Read More Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday November 22, 2024 Via Benzinga Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 November 22, 2024 Via ACCESSWIRE Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate November 21, 2024 Via ACCESSWIRE Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate November 19, 2024 Via ACCESSWIRE Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update November 07, 2024 Via ACCESSWIRE Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 06, 2024 Via ACCESSWIRE Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis November 18, 2024 Via ACCESSWIRE 10 Health Care Stocks With Whale Alerts In Today's Session November 13, 2024 Via Benzinga Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting November 05, 2024 Via ACCESSWIRE Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million October 29, 2024 Via ACCESSWIRE Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines September 10, 2024 Via Benzinga Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 September 03, 2024 Via ACCESSWIRE PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 August 06, 2024 Via InvestorPlace RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports August 01, 2024 Via ACCESSWIRE Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor July 31, 2024 Via ACCESSWIRE ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? July 28, 2024 Via Benzinga AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday July 24, 2024 Via Benzinga Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 July 22, 2024 Via ACCESSWIRE 3 Growth Stocks No One Is Watching (But They Should Be) July 11, 2024 Via InvestorPlace Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 June 28, 2024 Via Investor's Business Daily Topics Stocks Exposures US Equities Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control June 13, 2024 Via ACCESSWIRE The 3 Best Biotech Stocks to Buy in June 2024 June 05, 2024 Via InvestorPlace Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 May 31, 2024 Via ACCESSWIRE Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
